Telix Full Year Results 2025 Investor Webcast Notification
Rhea-AI Summary
Telix (ASX: TLX, NASDAQ: TLX) will report full year results for the period ended 31 December 2025 on Friday, 20 February 2026 AEDT (Thursday, 19 February 2026 EST).
An investor webcast and conference call is scheduled for 9:30 a.m. AEDT on 20 February 2026 (5:30 p.m. EST on 19 February 2026). Registration is available via the company webcast link.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
TLX gained 2.06% while key biotech peers were mixed: RARE -0.48%, APLS +3.64%, LGND -0.02%, MLTX -3.33%, ZLAB -1.56%, suggesting stock-specific factors ahead of results.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 20 | FY 2025 results | Positive | -0.4% | Reported FY 2025 revenue ~US$804M in line with upgraded guidance. |
| Jan 16 | Clinical trial update | Positive | +4.4% | First U.S. patient dosed in BiPASS Phase 3 prostate cancer diagnosis trial. |
| Jan 08 | Conference presentation | Positive | +1.7% | Planned pipeline and commercial overview at J.P. Morgan Healthcare Conference. |
| Dec 21 | Portfolio update | Positive | +3.2% | Precision medicine update; Illuccix China Phase 3 met primary endpoint. |
| Dec 10 | Strategic collaboration | Positive | +3.1% | Announced theranostics and EBRT clinical collaboration with Varian. |
Recent fundamentally positive news (revenue growth, trial progress, collaborations) has usually seen positive one-day reactions, with one slight pullback despite strong FY 2025 guidance.
Over the past few months, Telix reported strong commercial and clinical momentum. On Dec 10, 2025 it announced a strategic EBRT collaboration with Varian, followed by a precision medicine portfolio update on Dec 21, 2025. Early January 2026 brought a J.P. Morgan conference presentation and Q4 2025 results on Jan 20, 2026 showing FY 2025 revenue of ~US$804M. The BiPASS Phase 3 dosing update on Jan 16, 2026 highlighted pipeline advancement. Today’s webcast notice fits into this ongoing cadence of results and investor engagement.
Market Pulse Summary
This announcement schedules Telix’s full year 2025 results for 20 February 2026 and outlines an investor webcast at 9:30 a.m. AEDT. It follows recent disclosures of FY 2025 revenue of ~US$804M, strong Q4 growth, and multiple late-stage imaging programs and collaborations. Investors may focus on how the detailed results build on that trajectory, including revenue mix, progress across prostate and renal imaging studies, and any updated commercial or regulatory milestones.
AI-generated analysis. Not financial advice.
MELBOURNE, Australia and INDIANAPOLIS, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) advises that it will release its full year results for the period ended 31 December 2025 on Friday, 20 February 2026 AEDT (Thursday, 19 February 2026 EST).
An investor webcast and conference call will be held at 9:30 a.m. AEDT, Friday, 20 February 2026 (5:30 p.m. EST, Thursday, 19 February 2026).
Participants can register at the following link: https://edge.media-server.com/mmc/p/famdpwzh
About Telix Pharmaceuticals Limited
Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).
Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook.
Telix Investor Relations (Global)
Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Investor Relations and Corporate Communications
Email: kyahn.williamson@telixpharma.com
Telix Investor Relations (U.S.)
Annie Kasparian
Telix Pharmaceuticals Limited
Director Investor Relations and Corporate Communications
Email: annie.kasparian@telixpharma.com
This announcement has been authorized for release by Telix Pharmaceuticals Limited’s Company Secretary, Genevieve Ryan.
Legal Notices
Cautionary Statement Regarding Forward-Looking Statements.
You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.
The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.
This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, including the planned NDA resubmission for TLX101-Px and the planned BLA resubmission for TLX250-Px, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.
Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.
©2026 Telix Pharmaceuticals Limited. All rights reserved.
FAQ
When will Telix (TLX) release its full year results for the period ended 31 December 2025?
What time is the Telix (TLX) investor webcast and conference call for the FY2025 results?
How can investors register for the Telix (TLX) FY2025 results webcast?
Which reporting period does the Telix (TLX) FY2025 announcement cover?
Will the Telix (TLX) webcast include a Q&A with management on 20 February 2026?
